Drugs / 89Zr-DFO-daratumumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04467281 | Jun 2020 → Feb 2021 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-DFO-daratumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04467281 ↗ |
| Modality | Diagnostic / imaging agent | “The purpose of this study is to see if using the radioactive tracer 89Zr-DFO-daratumumab with PET/CT scans is a practical and effective way to view and monitor multiple myeloma” NCT04467281 ↗ |